TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women 18 years of age or older~* History of RLS symptoms for at least 15 nights/month~* Documented RLS symptoms, using the 7-day RLS Symptom Record, for at least 4 of the 7 consecutive evenings/nights during the night~* Total RLS severity score of 15 or greater on the International RLS (IRLS) Rating Scale at Visit 1 and at Visit 2~* Discontinuation of dopamine agonists and/or gabapentin , or other treatments for RLS (e.g. opioids, benzodiazepines) at least 2 weeks prior to Baseline~* If taking any prescription medication, therapy must have been stabilized for at least 3 months prior to Screening with no anticipated changes for the duration of the study~* Female subjects are eligible if of non-childbearing potential or not lactating, has a negative pregnancy, and agrees to use a highly effective method for avoiding pregnancy~* Body mass index of 34 or below~* Estimated creatinine clearance of ≥60 mL/min~* Provides written consent in accordance with all applicable regulatory requirements~Exclusion Criteria:~* History of a sleep disorder that may affect the assessment of RLS~* History of RLS symptom augmentation or end-of-dose rebound with previous dopamine agonist treatment~* Neurologic disease or movement disorder~* Other medical conditions or drug therapy that could affect RLS efficacy assessments or may present a safety concern~* Have clinically significant or unstable medical conditions~* Have active suicidal plan/intent or has had active suicidal thoughts in the past 6 months; has a history of suicide attempt

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK1838262 600 mg (Type: ACTIVE_COMPARATOR): Once-daily dose with food in the evening at approximately 5 PM
- GSK1838262 450 mg (Type: ACTIVE_COMPARATOR): Once-daily dose with food in the evening at approximately 5 PM
- GSK1838262 300 mg (Type: ACTIVE_COMPARATOR): Once-daily dose with food in the evening at approximately 5 PM
- GSK1838262 placebo match (Type: PLACEBO_COMPARATOR): Once-daily dose with food in the evening at approximately 5 PM

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Type 2 diabetes mellitus, being diagnosed according to the 1999 WHO criteria for at least 3 months~2. Age ≥ 18 years~3. BMI ≥ 25.0 kg/m2~4. HbA1c ≥ 7.0 %~5. Treatment with insulin with stable dose of at least 30 U/day (± 4 U/day), for at least 75 days~Exclusion Criteria:~1. Prior or current use of any PPAR-γ agonist~2. Recent use (\< 3 months) of an investigational drug~3. Pre-existing medical condition judged to preclude safe participation in the study~4. Contraindication/intolerance to study medication~5. Use of any drug which in the Investigator's opinion could interfere with the glucose level (e.g. systemic corticosteroids)~6. Diagnosed or receiving medication for heart failure, NYHA I to IV~7. Hospitalisation for a major CV event in the last 3 months, scheduled major CV intervention~8. Uncontrolled treated/untreated systolic blood pressure \>180 mmHg and/or diastolic blood pressure \> 95 mmHg~9. Known diabetic macular oedema~10. Hematuria~11. Serum creatinine \>130 μmol/l~12. ALT, AST, total bilirubin or alkaline phosphatase ≥ 2.5 times the upper limit of normal~13. Haemoglobin significantly (in the Investigators opinion, but not more than 1 mmol/L) below the lower limit of normal or haemoglobinopathy interfering with valid HbA1c assay~14. Pregnancy, breast feeding or planning pregnancy or not using adequate contraceptive methods (adequate contraceptive measures are an intrauterine device or oral contraceptives)~15. Mental incapacity, unwillingness, or language barrier precluding adequate understanding or cooperation~16. Abuse of alcohol or drugs, or presence of any condition that in the Investigators opinion may lead to poor adherence to study protocols~17. Cancer or any clinically significant disease or disorder, except for conditions associated to the type 2 diabetes, which in the Investigator's opinion could interfere with the results of the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Balaglitazone 10 mg per day (Type: EXPERIMENTAL): None
- Balaglitazone 20 mg per day (Type: EXPERIMENTAL): None
- Pioglitazone 45 mg per day (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of the Motilin Receptor Agonist, Erythromycin, on Hunger and Food Intake; Study of Role of Cholinergic Pathways

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Female or male subjects aged 18 to 60~* Subject is capable and willing to give informed consent~* Female volunteers of child bearing potential must use oral, injected or implanted hormonal methods of contraception~Exclusion criteria:~* Female volunteer is pregnant or breastfeeding~* Gastrointestinal diseases, major abdominal surgery~* Major psychiatric illnesses~* Volunteers that use drugs affecting the gastrointestinal tract or the central nervous system~* Allergy for macrolide antibiotics~* Allergy for atropine~* Severe heartburn~* Enlarged prostate~* Blockage of urinary tract~* Acute closed-angle glaucoma~* Myasthenia gravies~* Severe heart disease~* Thyrotoxicosis~* Fever~* Liver problems~* High blood pressure or fast heart rate~* Lung disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Erythromycin lactobionate (Type: ACTIVE_COMPARATOR): 40 mg erythromycin lactobionate was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %
- Erythromycin lactobionate with atropine (Type: ACTIVE_COMPARATOR): 40 mg erythromycin lactobionate was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %; Atropine sulfate was given as an i.v. bolus (15 µg/kg) followed by a continuous infusion of 15 µg/kg/h over 30 min
- Atropine (Type: PLACEBO_COMPARATOR): Atropine sulfate was given as an i.v. bolus (15 µg/kg) followed by a continuous infusion of 15 µg/kg/h over 30 min.~Infusion of saline as a placebo for erythromycin was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %
- Placebo (Type: PLACEBO_COMPARATOR): Infusion of saline was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %; also placebo for atropine was given as an i.v. bolus of saline followed by a continuous infusion over 30 min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Lasers in the Treatment of Scars

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 or older.~2. Fitzpatrick skin type I-IV.~3. Scars secondary to surgery or trauma.~4. Scar length minimum 4 cm in length.~Exclusion Criteria:~1. Scars less than 6 weeks old.~2. History of keloid scarring.~3. Use of isotretinoin currently or within 3 months of enrollment~4. Use of photosensitive medication currently or within 3 months of enrollment.~5. Pregnancy -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: t

Study Arms:
- Scar treated with Fraxel and CO2 laser (Type: OTHER): One half of scar is treated with Fraxel laser and the other half of scar is treated with CO2 laser.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Must be 20 years of age or older~2. Diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT) in both eyes. (OAG in one eye and OHT in the fellow eye is acceptable)~3. BCVA 0.1 or better in decimal unit using Landolt-C chart or its equivalent~4. Able and willing to give signed informed consent and following study instructions~Exclusion Criteria:~1. Clinically significant ocular diseases~2. Pseudoexfoliation or pigment dispersion component glaucoma, history of narrow angle closure glaucoma or narrow angles~3. Previous glaucoma intraocular surgery~4. Refractive surgery in either eye~5. Ocular trauma~6. Ocular infection or inflammation~7. Known hypersensitivity to benzalkonium chloride or excipient of netarsudil ophthalmic solution~8. Cannot demonstrate proper delivery of the eye drop~9. Clinically significant abnormalities in screen lab tests~10. Clinically significant systemic disease~11. Participation in any investigational study within 30 days of screening~12. Women of child-bearing potential who are pregnant, nursing, planning a pregnancy or not using a medically acceptable form of birth control

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Netarsudil Ophthalmic Solution 0.01% (Type: EXPERIMENTAL): 1 drop daily into each eye in the evening for 28 days
- Netarsudil Ophthalmic Solution 0.02% (Type: EXPERIMENTAL): 1 drop daily into each eye in the evening for 28 days
- Netarsudil Ophthalmic Solution 0.04% (Type: EXPERIMENTAL): 1 drop daily into each eye in the evening for 28 days
- Netarsudil Ophthalmic Solution Placebo (Type: PLACEBO_COMPARATOR): 1 drop daily into each eye in the evening for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria:~1. male gender~2. age 73 or younger~3. presence of CHD~4. HDL-C le 40 mg/dl~5. LDL-C le 140 mg/dl~6. triglycerides le 300 mg/dl~Exclusion Criteria:~Exclusion criteria:~1. significant medical illness~2. alcohol or substance abuse~3. evidence of cholecystitis or cholelithiasis~4. ejection fraction of lt 35%~5. current use of steroids, estrogens, immunosuppressive agents, oral coagulants, or lipid modifying drug.~6. allergic to gemfibrozil or fibric acid~7. refused informed consent

- Gender: MALE
- Minimum Age: None
- Maximum Age: 73 Years
- Healthy Volunteers: f

Study Arms:
- Gemfibrozil (Type: ACTIVE_COMPARATOR): 1200 mg slow-release gemfibrozil (Lopid-SR) once per day
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablets taken once per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infertile women aged 18-40 undergoing their first IVF/ICSI cycle that are in good physical and mental health and that have been diagnosed with problems in the fallopian tubes, mild endometriosis or have partners with decreased sperm quality.~* The participants must have a regular menstrual cycle, a normal uterus and 2 normal ovaries.~* The allowed body mass index is 17.5-32 Kg/m\^2.~Exclusion Criteria:~* Women with very high ovarian reserve, strong preference for either treatment, severe endometriosis, history of repeated miscarriage, couples with known problems in the chromosomes, history or high risk of producing blood cloths, women known to have chronic diseases, women recently participating in trials with non-registered drugs.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- FE 999049 + GnRH agonist (GONAPEPTYL) (Type: EXPERIMENTAL): None
- FE 999049 + GnRH antagonist (CETROTIDE) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is between 18-50 years old.~2. After 12 weeks gestation.~3. Diagnosed with ITP meeting the diagnostic criteria for immune thrombocytopenia.~4. Patients who have no response or relapsed after Corticosteroid or IVIG.~5. Patients developed refractoriness to platelet transfusion.~6. To show a platelet count \< 30×10\^9/L, and with bleeding manifestations.~7. Willing and able to sign written informed consent.~Exclusion Criteria:~1. Received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 3 months before the screening visit.~2. Received second-line ITP-specific treatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) within 3 months before the screening visit.~3. Current HIV infection or hepatitis B virus or hepatitis C virus infections.~4. Severe medical condition (lung, hepatic or renal disorder) other than chronic ITP. Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia)~5. Have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test.~6. Patients who are deemed unsuitable for the study by the investigator.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- rhTPO (Type: EXPERIMENTAL): rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10\^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Hygiene Procedures on Reduction of Oral Malodor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of oral malodor~* At least 20 functional teeth~* No systemic diseases~* No severe dental diseases~Exclusion Criteria:~* Habit of smoking and betel quid chewing~* Oral malodor by food and other craniofacial abnormalities~* Current use of any kind of mouthwash

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- group 1: drug (Type: EXPERIMENTAL): Drug: group 1: drug: chlorine dioxide 12ml chlorine dioxide (ClO2) mouthwash two times per day, for three consecutive weeks
- group 2: device: (Type: EXPERIMENTAL): group 2: device: small tooth brush for tongue cleaning small tooth brush for tongue cleaning

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Early onset nosocomial pneumonia in patients under mechanical ventilation since at least 24 h Patients aged 18 years or more The patient must be able to receive either one of the two arms of treatment defined for the study Information on the patient and his family informed consent obtained during the first three days Bacteria sensitive to the specified antibiotic regimen~Exclusion Criteria:~* Patients do not match the criteria for inclusion~* 18 years of age, pregnant Patients~* Another infectious outbreak documented the day of the BAL.~* Patients with acquired immunosuppression (blood diseases, HIV,...), induced (immunosuppressive drugs, cancer, radiation therapy) or congenital.~* Steroids for a period exceeding 15 days.~* Leukopenia (1000 GB/mm (or neutropenia (500 PN/mm)~* Purulent pleural effusion, pulmonary abscess~* Cystic fibrosis~* Antibiotic treatment according to the following terms:~  1. Ongoing curative antibiotic therapy~ 2. Antibiotics within 3 days before the diagnosis of VAP, except surgical antibiotic prophylaxis (defined according to the consensus conference antibiotic prophylaxis in the surgical environment in adult December 11, 1992) (27)~ 3. Use of antibiotics not authorized in the study (see list)~* Allergy to antibiotics used in the study~* Inclusion in another study assessing antibiotic treatment, either the treatment or prevention of nosocomial pulmonary disease~* Refusal to participate~* Lack of informed consent by the patient or his family

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 8 days of antibiotic treatment (Type: EXPERIMENTAL): Patients will receive a combination antibiotic during 5 days and then 3 days of a single Beta Lactam antibiotic
- 15 days antibiotic treatment (Type: ACTIVE_COMPARATOR): All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for 10 days according to the group. The beta-lactam antibiotics will be administered in high doses during the first 3 days of treatment. Aminoglycosides will be administered in a single daily dose, with a loading dose the first day of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cohort Study in Uganda Comparing Artesunate + Amiodaquine (Coarsucam) Versus Artemether + Lumenfantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Specific inclusion criteria for initial enrollment:~* Confirmed mono infection with Plasmodium falciparum, with parasite density ≥2000 asexual forms per µl of blood,~Inclusion criteria for each attacks:~* Body weight ≥5 kg~* Able to be treated by oral route~* Fever (axillary temperatur ≥37.5 degrees Celsius) at D0 or history of fever within the previous 24 hours~* Confirmed Plasmodium falciparum infection with positive paratesimia~* Haemoglobin value ≥5.0 g/dl~Exclusion Criteria:~Specific exclusion criteria for initial enrollment:~* Patient participating in another ongoing clinical trial~* Allergy to one of the investigational medicinal products~* History of hepatic and (or) haematological impairment during treatment with amodiaquine~* History of cardiac disease~* Concomitant febrile illness~Exclusion criteria for each attacks:~* Presence of at least one danger sign of malaria: recent history of convulsions (1-2 within 24h), unconsciousness state, lethargy, unable to drink or breast feed, vomiting everything, unable to stand/sit due to weakness~* Severe concomitant disease or known disturbances of electrolyte balance such as hypokalaemia or hypomagnesaemia~* Intake of medication metabolized by cytochrome CYP 2D6 (e.g. metoprolol, flecainide, imipramine, amitriptyline, clomipramine) at the time of inclusion~* Intake of drugs known to inhibit CYP 2A6 (e.g. methoxsalem, pilocarpine, tranylcypromine) and/or 2C8 cytochromes (e.g. trimethoprim, ritonavir, ketoconazole, montelukast, gemfibrozil) at the time of inclusion~* Intake of medication known to prolong the QTc interval, such as class IA and III antiarrythmics, neuroleptics, antidepressant agents, certain antibiotics including drugs in the macrolide class, fluoroquinolones, imidazole and triazole, antifungal agents, certain non-sedative anthistamines (terfenadine, astemizole) and cisapride at the time of inclusion~* Patient having received artesunate + amiodaquine or artemether + lumefantrine at suitable dosage within the previous 2 weeks.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Coarsucam double-layer artesunate/amiodaquine tablets
- 2 (Type: ACTIVE_COMPARATOR): Coartem (artemether/lumefantrine) fixed-dose combination tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete